.jpg&w=1200&q=75)
Innovative CAR-T Cell Therapy Shows Promise Against Aggressive Brain Tumors in Mice
Cytokine-armored CAR-T cell therapy successfully attacks aggressive brain tumors in mice
Image: Medical News
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have developed a novel cytokine-armored CAR-T cell therapy that enhances the immune response against glioblastoma, a highly aggressive brain cancer. This approach not only improves tumor control but also reduces side effects, paving the way for potential clinical trials in patients with high-grade gliomas.
- 01The therapy utilizes CAR-T cells engineered to release immune-stimulating proteins IL-12 and DR-18, enhancing the body's immune response against glioblastoma.
- 02Combining this therapy with a second CAR-T strategy targeting VEGF helps mitigate side effects while maintaining anti-tumor efficacy.
- 03The study demonstrated that the cytokine-armored CAR-T cells could eliminate tumors even when cancer cells lacked the specific target recognized by the CAR-T cells.
- 04Researchers are preparing for a Phase 1 clinical trial to evaluate the therapy's effectiveness and safety in human patients with recurrent high-grade gliomas.
- 05The findings were published in the journal Cancer Research, indicating a significant advancement in treating solid tumors that have historically resisted CAR-T cell therapy.
Advertisement
In-Article Ad
Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have introduced a groundbreaking cytokine-armored CAR-T cell therapy aimed at combatting glioblastoma, one of the most aggressive and treatment-resistant brain cancers. This innovative therapy enhances the immune system's ability to attack tumors by reprogramming CAR-T cells to secrete immune-stimulating proteins, specifically IL-12 and DR-18. In preclinical trials using mouse models, this approach has shown improved tumor control, even against heterogeneous cancer cell populations that typically evade treatment. Importantly, the therapy was paired with a second CAR-T strategy targeting vascular endothelial growth factor (VEGF), which reduced side effects while preserving strong anti-tumor activity. The study's lead author, Yvonne Chen, PhD, emphasized the potential of this therapy to engage naturally occurring immune cells, which can recognize diverse tumor antigens. The researchers are optimistic about moving forward with a Phase 1 clinical trial to evaluate this therapy's safety and efficacy in human patients, marking a significant step forward in the treatment of high-grade gliomas.
Advertisement
In-Article Ad
This innovative treatment could significantly improve outcomes for patients suffering from glioblastoma, a cancer with limited effective treatment options.
Advertisement
In-Article Ad
Reader Poll
Do you believe CAR-T cell therapy could revolutionize cancer treatment?
Connecting to poll...
Read the original article
Visit the source for the complete story.